National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, People's Republic of China.
Key Laboratory for Parasitology and Vector Biology, MOH of China, WHO Collaborating Center for Tropical Diseases, National Center for International Research on Tropical Diseases, Shanghai, People's Republic of China.
J Med Virol. 2017 Jan;89(1):71-78. doi: 10.1002/jmv.24606. Epub 2016 Jul 11.
Group A rotavirus (RVA) is one of the leading cause of acute diarrhea worldwide, the RVA-related disease burden and the genotypes of RVA is important reference to introduce RVA variance to national immunisation programmes, 1,121 diarrhea cases and 319 healthy controls were recruited from four sentinel hospital outpatient from July 2014 to June 2015. The prevalence of RVA was 244 (21.8%) in gastroenteritis cases and in 12 (3.8%) in healthy controls across all age group (OR = 7.12, 95%CI = 3.93-12.89); the detection rate of RVA in diarrhea patients under 5 years was more higher than in diarrhea cases over 5 years (26.1%, 222/850; 8.1%, 22/271, respectively, P = 0.000). Of 244 RVA strains isolated from acute diarrhea cases, G9 (66.4%) was predominant G genotype, followed by G3 (18.7%), G1 (8.9%), and G1G3 (3.8%); P[8] was the overwhelming prevalence P genotype, followed by P[4] (4.7%); G9P[8] (54.9%) was most common G and P Combination, followed by G3P[8] (17.6%) and G1[8] (8.6%). The conclusion of the study was important to provide reference for introducing the RVA vaccine to prevent and control RVA-associated disease burden. J. Med. Virol. 89:71-78, 2017. © 2016 Wiley Periodicals, Inc.
A 组轮状病毒(RVA)是全球急性腹泻的主要病因之一,RVA 相关疾病负担和 RVA 基因型对于将 RVA 变异引入国家免疫规划具有重要参考意义。本研究于 2014 年 7 月至 2015 年 6 月,从 4 家哨点医院门诊招募了 1211 例腹泻病例和 319 例健康对照。在所有年龄段中,胃肠炎病例中 RVA 的流行率为 244 例(21.8%),健康对照中为 12 例(3.8%)(OR=7.12,95%CI=3.93-12.89);5 岁以下腹泻患者中 RVA 的检出率高于 5 岁以上腹泻患者(26.1%,222/850;8.1%,22/271,P=0.000)。从急性腹泻病例中分离的 244 株 RVA 株中,G9(66.4%)是主要的 G 基因型,其次是 G3(18.7%)、G1(8.9%)和 G1G3(3.8%);P[8]是压倒性流行的 P 基因型,其次是 P[4](4.7%);G9P[8](54.9%)是最常见的 G 和 P 组合,其次是 G3P[8](17.6%)和 G1[8](8.6%)。本研究的结论为引入 RVA 疫苗预防和控制 RVA 相关疾病负担提供了参考。J. Med. Virol. 89:71-78, 2017. © 2016 Wiley Periodicals, Inc.